ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 22.22% | 50.44% | 46.62% | 28.93% | 14.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.22% | 50.44% | 46.62% | 28.93% | 14.60% |
| Cost of Revenue | -39.14% | 60.57% | 100.48% | 331.81% | 43.25% |
| Gross Profit | 365.18% | 42.68% | 16.22% | -383.85% | -45.89% |
| SG&A Expenses | -27.15% | -20.81% | 13.51% | 105.89% | 21.35% |
| Depreciation & Amortization | -6.71% | 18.57% | -22.13% | 5.18% | -32.18% |
| Other Operating Expenses | -17.76% | -4.50% | 95.91% | 2,027.59% | -66.21% |
| Total Operating Expenses | -7.76% | -8.40% | 2.46% | 122.59% | 0.80% |
| Operating Income | 8.51% | 9.29% | -1.37% | -124.72% | -0.49% |
| Income Before Tax | 8.17% | 48.77% | 30.63% | -403.84% | 44.23% |
| Income Tax Expenses | 20.38% | 20.51% | -6.78% | -607,871.43% | -20.77% |
| Earnings from Continuing Operations | 8.11% | 48.83% | 30.75% | -307.55% | 44.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.11% | 48.83% | 30.75% | -307.55% | 44.38% |
| EBIT | 8.51% | 9.29% | -1.37% | -124.72% | -0.49% |
| EBITDA | 8.94% | 13.08% | -11.20% | -132.76% | -13.59% |
| EPS Basic | 11.16% | 66.98% | 62.39% | -124.17% | 69.29% |
| Normalized Basic EPS | 11.03% | 58.09% | 62.20% | 31.28% | 57.03% |
| EPS Diluted | 11.16% | 65.91% | 60.02% | -125.57% | 69.29% |
| Normalized Diluted EPS | 11.03% | 58.09% | 62.20% | 31.28% | 57.03% |
| Average Basic Shares Outstanding | 3.38% | 54.88% | 83.86% | 81.77% | 81.21% |
| Average Diluted Shares Outstanding | 3.38% | 54.88% | 83.86% | 81.77% | 81.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
